Mark Cragg

Professor of Experimental Cancer Research
University of Southampton
Mark Cragg
Mark Cragg is Professor of Experimental Cancer Biology in the Cancer Sciences Unit of Southampton University Faculty of Medicine. He obtained his PhD in 1998 and did his postdoctoral studies in Southampton with Martin Glennie and in Melbourne, Australia with Andreas Strasser before starting his own group in 2007. His research concerns how therapeutics result in tumour regression with a focus on antibodies and small molecules. The aim is to understand how these therapeutics delete tumour cells, how resistance occurs and how it might be overcome. Over the last decade, he has investigated many different therapeutic agents such as rituximab, bexxar, imatinib, gefitinib, cetuximab and tarceva and has been involved in the development of next generation antibody reagents such as ofatumumab and obinutuzumab, as well as first in class antibodies such as BI-1206.


No data was found

Other Speakers